Medicine and Dentistry
Acute Coronary Syndrome
18%
Acute Heart Infarction
26%
Angina pectoris
42%
Angina Pectoris
25%
Angiography
14%
Arm
8%
C Reactive Protein
11%
Cardiac Magnetic Resonance Imaging
13%
CD34 Antibody
22%
Coronary Angiography
9%
Coronary Artery
21%
Coronary Artery Disease
41%
Coronary Artery Obstruction
17%
Coronary Flow Reserve
34%
Coronary Microvascular Dysfunction
43%
Diabetes
18%
Diabetes Mellitus
20%
Doppler Echocardiography
14%
Drug-Eluting Stent
26%
Everolimus
39%
Hazard Ratio
18%
Heart Death
21%
Heart Left Ventricle Ejection Fraction
10%
Heart Muscle Ischemia
16%
Infarction
19%
Intention-to-Treat Analysis
10%
Intravascular Ultrasound
43%
Ischemia
13%
Lung
11%
Magnesium
14%
Major Adverse Cardiac Event
11%
Myocardial Infarction
35%
Non ST Segment Elevation Myocardial Infarction
23%
Noninferiority Trial
10%
Optical Coherence Tomography
57%
Paclitaxel
11%
Percutaneous Coronary Intervention
71%
Primary Percutaneous Coronary Intervention
27%
Randomized Clinical Trial
8%
Rapamycin
89%
Reperfusion Injury
12%
Revascularization
20%
ST Segment Elevation Myocardial Infarction
47%
Stable Angina Pectoris
10%
Stenosis
9%
Stent Thrombosis
18%
Target Lesion
31%
Target Lesion Revascularization
27%
Umirolimus
33%
Vasospasm
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylcysteine
5%
Acute Coronary Syndrome
23%
Acute Heart Infarction
29%
Angina Pectoris
19%
Atorvastatin
7%
C Reactive Protein
7%
Cardiovascular Disease
5%
Cardiovascular Risk
6%
CD34 Antibody
28%
Contrast Induced Nephropathy
5%
Coronary Artery Disease
35%
Coronary Artery Spasm
5%
Diabetes Mellitus
7%
Dicarbonate
5%
Dipyridamole
11%
Everolimus
34%
Ezetimibe
11%
Heart Death
35%
Heart Infarction
44%
Heart Muscle Injury
8%
Heart Muscle Ischemia
18%
Infarction
23%
Interleukin 6
5%
Ischemia
11%
Ischemic Heart Disease
6%
Left Ventricular Diastolic Dysfunction
5%
Lipoprotein
5%
Low Density Lipoprotein Cholesterol
6%
Major Adverse Cardiac Event
14%
Melatonin
5%
Muscle Spasm
5%
Noninferiority Trial
13%
Pentraxin 3
5%
Placebo
10%
Placebo-Controlled Study
6%
Polyethylene Terephthalate
5%
Prospective Cohort Study
5%
Randomized Clinical Trial
13%
Rapamycin
100%
Reperfusion Injury
12%
Respiratory Tract Allergy
5%
Rosuvastatin
11%
ST Segment Elevation Myocardial Infarction
58%
Stable Angina Pectoris
9%
Stainless Steel
9%
Statin (Protein)
12%
Stenosis
11%
Stent Thrombosis
28%
Umirolimus
51%
Zotarolimus
5%
